Tambocor

Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Ventricular + 11 more
Treatment
22 FDA approvals
20 Active Studies for Tambocor

What is Tambocor

FlecainideThe Generic name of this drug
Treatment SummaryFlecainide is a medication used to treat abnormal heart rhythms such as atrial fibrillation and flutter. It was first developed in 1966 and synthesized in 1972, and was officially approved by the FDA in 1985. Flecainide belongs to a class of medications called Class I anti-arrhythmic agents, which also includes drugs like encainide and propafenone.
Tambocoris the brand name
Tambocor Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tambocor
Flecainide
1985
82

Approved as Treatment by the FDA

Flecainide, commonly known as Tambocor, is approved by the FDA for 22 uses like Tachycardia, Supraventricular and Supraventricular tachycardia .
Tachycardia, Supraventricular
Supraventricular tachycardia
Atrial Fibrillation
severe ventricular arrhythmias
prophylaxis of severe Paroxysmal supraventricular tachycardia
prophylaxis of severe Sustained ventricular tachycardia
Ventricular Tachycardia
severe Supraventricular Tachycardias
severe Paroxysmal atrial fibrillation
severe Atrioventricular nodal reentrant tachycardia
prophylaxis of severe Paroxysmal atrial fibrillation
prophylaxis of severe Atrioventricular nodal reentrant tachycardia
severe Sustained ventricular tachycardia
prophylaxis of severe ventricular arrhythmias
severe Paroxysmal supraventricular tachycardia
prophylaxis of severe Supraventricular Tachycardias
Paroxysmal supraventricular tachycardia
Paroxysmal supraventricular tachycardia
Tachycardia, Ventricular
Tachycardia, Ventricular
Tachycardia, Atrioventricular Nodal Reentry
Tachycardia, Atrioventricular Nodal Reentry

Effectiveness

How Tambocor Affects PatientsFlecainide is a medication used to treat heart arrhythmias by blocking sodium and potassium ion channels in the heart and increasing the amount of energy needed for the heart to beat. It needs to be taken once a day, but it is important to be careful with this medication as it can easily become dangerous if the dose is too high. People with existing structural heart disease or poor heart function should not take flecainide.
How Tambocor works in the bodyFlecainide works by blocking sodium channels in the heart and preventing potassium channels from opening. This helps to prolong the refractory period of the heart and lengthen the action potentials in the Purkinjie fibers and muscle fibers. It also blocks the release of calcium from the sarcoplasmic reticulum, reducing the depolarization of cells.

When to interrupt dosage

The amount of Tambocor is contingent upon the diagnosed disorder, including Paroxysmal supraventricular tachycardia, severe Atrioventricular nodal reentrant tachycardia and Tachycardia, Ventricular. The dosage fluctuates, in accordance with the mode of administration (e.g. Tablet - Oral or Oral) detailed in the next table.
Condition
Dosage
Administration
Paroxysmal supraventricular tachycardia
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Tachycardia, Atrioventricular Nodal Reentry
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Tachycardia, Ventricular
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Tachycardia, Supraventricular
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
prophylaxis of severe Paroxysmal atrial fibrillation
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Tachycardia, Ventricular
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
prophylaxis of severe ventricular arrhythmias
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Supraventricular tachycardia
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Ventricular Tachycardia
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Tachycardia, Atrioventricular Nodal Reentry
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Paroxysmal supraventricular tachycardia
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Atrial Fibrillation
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
severe ventricular arrhythmias
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet
Atrial Fibrillation
100.0 mg, , 50.0 mg, 150.0 mg
Tablet - Oral, Oral, , Tablet

Warnings

Tambocor has five counter-indications, meaning it should not be taken when experiencing the conditions in the following table.Tambocor Contraindications
Condition
Risk Level
Notes
Bundle-Branch Block
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Atrioventricular Block
Do Not Combine
persistent second-degree atrioventricular block
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Flecainide may interact with Pulse Frequency
There are 20 known major drug interactions with Tambocor.
Common Tambocor Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Flecainide.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Flecainide.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Flecainide is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Flecainide is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Flecainide is combined with Artemether.
Tambocor Toxicity & Overdose RiskThe lethal dose of flecainide in rats is 1346mg/kg and in mice is 170mg/kg. For those who overdose, symptoms may include changes in their heart's electrical activity such as a slower heartbeat, a longer time between heartbeats, a longer QRS duration, a longer QT interval, increased T wave size, lower heart rate, and weaker heart contractions. Low blood pressure or death may also occur. Treatment should involve providing supportive care and administering drugs to help the heart function. Hemodialysis is not expected to help remove flecainide from the bloodstream.

Tambocor Novel Uses: Which Conditions Have a Clinical Trial Featuring Tambocor?

176 active studies are examining the potential of Tambocor to reduce severe ventricular arrhythmias, provide prophylaxis against severe ventricular arrhythmias, and treat Ventricular Tachycardia.
Condition
Clinical Trials
Trial Phases
prophylaxis of severe Paroxysmal atrial fibrillation
0 Actively Recruiting
Atrial Fibrillation
94 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1
Paroxysmal supraventricular tachycardia
0 Actively Recruiting
severe ventricular arrhythmias
0 Actively Recruiting
Ventricular Tachycardia
13 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Early Phase 1
Tachycardia, Atrioventricular Nodal Reentry
0 Actively Recruiting
Tachycardia, Ventricular
0 Actively Recruiting
Tachycardia, Ventricular
0 Actively Recruiting
Tachycardia, Atrioventricular Nodal Reentry
0 Actively Recruiting
prophylaxis of severe ventricular arrhythmias
0 Actively Recruiting
Atrial Fibrillation
0 Actively Recruiting
Tachycardia, Supraventricular
1 Actively Recruiting
Phase 4
Paroxysmal supraventricular tachycardia
0 Actively Recruiting
Supraventricular tachycardia
0 Actively Recruiting

Tambocor Reviews: What are patients saying about Tambocor?

5Patient Review
3/9/2013
Tambocor for A Type of Fast Heartbeat - Paroxysmal Atrial Tachycardia
After taking this medication for an extended period of time with no positive results, I was taken off of it. Ablation was attempted but unsuccessful. I experienced several VTach episodes where my heart rate would spike for 15 minutes straight. I was hospitalized and put back on Tambocor at a higher dose. After increasing the dosage and taking it for a full month, I have only had 3 decent days with minimal PVCs.
5Patient Review
4/10/2014
Tambocor for Atrial Fibrillation
Initially, I was only prescribed one 50mg tablet to be taken twice a day. This did not work for me, so my dosage was increased to two 50mg tablets per day. This change has been very effective; it's been over two weeks since my last episode.
5Patient Review
3/5/2012
Tambocor for A Type of Fast Heartbeat - Paroxysmal Atrial Tachycardia
4.7Patient Review
12/21/2011
Tambocor for Atrial Fibrillation
4Patient Review
4/17/2013
Tambocor for Paroxysmal Atrial Fibrillation
Since taking this medication, I have felt very anxious and shaky.
4Patient Review
8/2/2012
Tambocor for Atrial Fibrillation
4Patient Review
9/6/2012
Tambocor for Atrial Fibrillation
3.7Patient Review
9/3/2019
Tambocor for Paroxysmal Atrial Fibrillation
I have been dealing with AFib for a while now, and this medication has really helped to lessen the frequency and severity of my episodes. I still experience some chest pain and palpitations, but it is much better than it was before.
3.3Patient Review
11/11/2021
Tambocor for Atrial Fibrillation
I've only been on this for three weeks, and the only side effect I've noticed is shortness of breath. I contacted my doctor, but they haven't gotten back to me yet; as a result, I ended up cutting the dose myself. This has made a big difference--I no longer have shortness of breath. Instead of taking 50 mg twice a day, I am now taking one 50 mg at night and only a half in the day hours. Recently, I had the Cardioversion which put me back to a normal rhythm.
3Patient Review
7/24/2013
Tambocor for Heart Ventricle Rhythm Problem
The treatment is working which I'm happy about, though the side effects are quite troublesome. Anxiety, hair loss, and shortness of breath have all been issues.
3Patient Review
3/30/2012
Tambocor for Life-Threatening Rapid Ventricular Heartbeat
1.3Patient Review
10/5/2013
Tambocor for Atrial Fibrillation Electrically Shocked to Normal Rhythm
I had a really bad reaction to this drug. It was like poison to my system. I'm going to London to get the Tambacore brand instead.
1Patient Review
5/29/2013
Tambocor for Atrial Fibrillation
Although this is technically effective, I am now having hand tremors and anxiety. These are probable side effects that should be considered before taking the medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tambocor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are 3 side effects of flecainide?

"The person may experience shortness of breath, wheezing, difficult or labored breathing, fast or irregular heartbeat, dizziness, lightheadedness, or fainting."

Answered by AI

What is the medicine Tambocor used for?

"This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat. These include conditions such as persistent ventricular tachycardia and paroxysmal supraventricular tachycardia. The medication is used to restore normal heart rhythm and maintain a regular, steady heartbeat."

Answered by AI

What are the most common side effects of flecainide?

"Stomach problems. Symptoms may include: constipation, bloating, gas, diarrhea, and abdominal pain. Vision problems. Symptoms may include: blurred vision, double vision, and decreased vision. Low blood pressure. Symptoms may include: dizziness, lightheadedness, fainting, and fatigue. Uncontrollable shaking of parts of your body, such as your hands, arms, head, or legs. Headache."

Answered by AI

Does Tambocor lower heart rate?

"You may experience nausea, vomiting, slow heart rate, fainting, or seizure (convulsions) if you overdose on Flecainide (Tambocor)."

Answered by AI

Clinical Trials for Tambocor

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA
The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
Phase 4
Waitlist Available
Inova Alexandria Hospital
Have you considered Tambocor clinical trials? We made a collection of clinical trials featuring Tambocor, we think they might fit your search criteria.Go to Trials
Image of Mission Cardiovascular Research Institute in Fremont, United States.

REGN7508 + REGN9933 for Atrial Fibrillation

18+
All Sexes
Fremont, CA
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Phase 2
Recruiting
Mission Cardiovascular Research Institute (+4 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals
Image of The Cleveland Clinic in Cleveland, United States.

Metabolic Surgery for Atrial Fibrillation

18 - 80
All Sexes
Cleveland, OH
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Phase 4
Waitlist Available
The Cleveland ClinicAli AminaniEthicon, Inc.
Have you considered Tambocor clinical trials? We made a collection of clinical trials featuring Tambocor, we think they might fit your search criteria.Go to Trials
Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Alcohol Abstinence for Atrial Fibrillation

18+
All Sexes
San Francisco, CA
Per the 2021 National Survey on Drug Use and Health administered by the U.S. Department of Health and Human Services, 85% of all American adults consume alcohol. Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 10 million individuals in U.S., comprising 4.5% of the adult population. Although alcohol abstinence clearly reduces AF in heavy drinkers, observational data comparing the health effects of limited consumption versus abstention are conflicting. The Mediterranean diet is one of the few that has demonstrated clear cardiovascular benefits in a randomized study-this diet allows for the consumption of red wine (or high polyphenol/ low alcohol alcohol), generally not more than one drink in 24 hours, with meals, avoiding spirits and binge drinking. The effect of the "Mediterranean drinking pattern" on AF risk compared to alcohol abstinence remains unknown. This single center, randomized, controlled trial aims to compare the effects of a digital health intervention to encourage durable alcohol abstinence versus allowing guideline-adherent moderate alcohol consumption on AF severity. The knowledge gained from this study may be used to determine optimal thresholds for alcohol use among AF patients.
Recruiting
Has No Placebo
UCSF Medical Center at ParnassusGregory M Marcus, MD, MAS
Have you considered Tambocor clinical trials? We made a collection of clinical trials featuring Tambocor, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security